Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
CJC/Ipamorelin blend vs. Cagrilintide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
CJC/Ipamorelin blend is distinguished by an informal CJC-1295 no DAC / Mod GRF(1-29) plus ipamorelin combination label. Different upstream receptors share a downstream GH/IGF-1 axis, but no direct blend study demonstrates synergy; Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
CJC/Ipamorelin blend is distinguished in the current record by an informal CJC-1295 no DAC / Mod GRF(1-29) plus ipamorelin combination label. Different upstream receptors share a downstream GH/IGF-1 axis, but no direct blend study demonstrates synergy. Cagrilintide is distinguished by long-acting amylin analogue with amylin- and calcitonin-receptor activity; it is not a GLP-1 receptor agonist and is not the same evidence record as CagriSema. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceCagrilintide
CJC/Ipamorelin blend: No direct blend evidence. Cagrilintide: Developing human evidence.
Regulatory historyComparable
CJC/Ipamorelin blend: Not approved; informal combination. Cagrilintide: Investigational — Phase 3.
Mechanistic breadthComparable
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
CJC/Ipamorelin blend
- No direct combination study located
- GH and IGF-1 pharmacology — no-DAC CJC mechanistic evidence and IV ipamorelin human evidence
- Postoperative recovery — ipamorelin component only
- Body composition, sleep, and recovery — promoted, not demonstrated
Cagrilintide
- Weight management
- Appetite and energy intake
- Obesity with type 2 diabetes
- Visceral and ectopic fat
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
CJC/Ipamorelin blendNot approved; informal label
No FDA-approved CJC-1295 no DAC/ipamorelin fixed-combination product was located. Ingredient-level advisory actions do not approve the blend.
CagrilintideInvestigational
Investigational. No FDA-approved standalone cagrilintide product, consumer dose, reconstitution method, or official storage procedure.
Evidence depthEvidence, not a winner
CJC/Ipamorelin blendNo direct blend study
No direct combination evidence and no located controlled human study of the no-DAC CJC component. Ipamorelin has limited intravenous human pharmacology and a negative Phase 2 efficacy study.
CagrilintidePhase 2 + Phase 3 pending
One published 706-participant Phase 2 monotherapy trial, a 105-participant thorough-QT study, sponsor-reported Phase 3 component-arm data, and two active dedicated Phase 3 RENEW trials without posted results.
Weight outcomesEvidence, not a winner
CJC/Ipamorelin blendNo dedicated evidence
No controlled human weight-management or body-composition study of the no-DAC CJC/Ipamorelin blend was located.
CagrilintidePeer-reviewed Phase 2
Phase 2 reported mean reductions of 6.0% to 10.8% across studied cagrilintide arms versus 3.0% placebo at 26 weeks. A sponsor-reported Phase 3 component arm later reported 11.8% versus 2.3% at 68 weeks under an efficacy estimand.
Type 2 diabetesEvidence, not a winner
CJC/Ipamorelin blendNo dedicated evidence
No controlled human glucose-control or diabetes-outcome study of the blend was located.
CagrilintidePhase 3 registered
RENEW 2 is studying standalone cagrilintide in adults with overweight or obesity and type 2 diabetes; no results were posted by the cutoff.
Obstructive sleep apnoeaEvidence, not a winner
CJC/Ipamorelin blendNo dedicated evidence
No controlled human obstructive-sleep-apnoea study of the blend was located.
CagrilintideNo dedicated evidence
No dedicated completed controlled human obstructive-sleep-apnoea outcome study was located.
Cardiovascular outcomesEvidence, not a winner
CJC/Ipamorelin blendNo outcomes program
No human cardiovascular outcomes program for the blend was located.
CagrilintideQT study only
A 105-participant thorough-QT study found no clinically relevant QTc prolongation at the tested exposure. That narrow result is not a cardiovascular outcomes trial.
Administration and handlingEvidence, not a winner
CJC/Ipamorelin blendNo established process
No approved or trial-established blend route, ratio, dose, reconstitution process, or storage condition exists. CJC-1295 DAC protocols involve a different active moiety.
CagrilintideTrial descriptions only
Published and registered studies describe once-weekly subcutaneous administration under protocol-specific escalation. These are trial descriptions, not approved dosing instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- No-DAC CJC formulation, component ratio, compatibility, combined pharmacokinetics and GH/IGF-1 response, interactions, immunogenicity, safety, and meaningful clinical outcomes.
- Whether the dedicated RENEW Phase 3 trials confirm long-term standalone efficacy and safety in people with and without type 2 diabetes.
Community Intelligence
Emerging patterns, clearly separated from evidence
CJC/Ipamorelin blend
No community experiences yetBe the first account holder to contribute.
Cagrilintide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.